Skopos Bio

Developing next-generation radiopharmaceutical therapies for hard-to-treat cancers.

Cover Block

Public sources

Field	Value
Name	Skopos Bio
Tagline	Developing next-generation radiopharmaceutical therapies for hard-to-treat cancers. [Skopos Bio, retrieved 2026]
Headquarters	Melbourne, Australia [Drug Discovery World, October 2026]
Founded	2024 [EM Advisory, October 2026]
Stage	Seed [AFR, October 2026]
Business Model	Other
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	Oceania
Growth Profile	Venture Scale
Founding Team	Academic Spinout [Drug Discovery World, October 2026]
Funding Label	Seed
Total Disclosed	Approximately US$8.4 million [AFR, October 2026]

Executive Summary

PUBLIC Skopos Bio is an Australian radiopharmaceutical startup developing targeted radioactive molecules for cancer, and it merits investor attention now because it emerged publicly in October 2026 with a disclosed AUD$12 million seed round to advance a Peter MacCallum Cancer Centre spinout toward the clinic [AFR, October 2026] [Drug Discovery World, October 2026]. The founding story is unusually specific for a company this early: Skopos was formed in 2024 out of Melbourne research talent tied to Peter Mac, with public coverage and the company site pointing to a theranostics strategy that pairs imaging and treatment, initially in prostate cancer [Drug Discovery World, October 2026] [Skopos Bio] [Peter MacCallum Cancer Centre].

The product concept is straightforward, even if the biology is still preclinical. Skopos is building radioligand therapies designed to bind to cancer cells and deliver radiation directly to tumours while limiting exposure to healthy tissue, and the early differentiation appears to rest less on a commercial platform claim than on target selection and founder domain depth in prostate theranostics [EM Advisory, October 2026] [LinkedIn] [Skopos Bio].

That team profile is the main public asset at this stage. Michael Hofman is listed by Peter Mac as Director of the Prostate Theranostics and Imaging Centre of Excellence, Mohammad Haskali is Peter Mac's inaugural Chief Radiopharmaceutical Scientist, and Luc Furic leads Translational Prostate Cancer Research, giving the company a founder bench that maps closely to radiopharmaceutical discovery and translation rather than generalist biotech formation [Peter MacCallum Cancer Centre] [The University of Melbourne].

On funding, public reports converge on an AUD$12 million seed round, equivalent to roughly US$8.3 million to US$8.4 million, backed by Tenmile, Tin Alley Ventures, and Yosemite [AFR, October 2026] [EM Advisory, October 2026] [Signalbase, October 2026]. The business model is not yet articulated in operating detail, but the public record supports reading Skopos as a venture-scale therapeutics company whose next value inflection depends on advancing preclinical programs toward human trials rather than on near-term revenue [SmartCompany] [Drug Discovery World, October 2026].

Over the next 12 to 18 months, the practical watchpoints are scientific rather than commercial: whether Skopos can translate its academic-origin thesis into a credible preclinical package, define its lead candidate and target profile with more precision, and show a regulatory path toward first-in-human studies [Skopos Bio] [SmartCompany] [EM Advisory, October 2026]. The initial disease focus also gives the company a large clinical backdrop, with one trade publication citing roughly 1.5 million global prostate cancer diagnoses each year, but the investment case still turns on whether Skopos can produce data that separates a promising radiopharma concept from a financeable development program [Drug Discovery World, October 2026].

Lightly corroborated -- Core company formation, founder roles, and financing are supported by multiple public sources, but product-stage details and several pipeline claims remain company or trade-publication sourced.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	Other
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	Oceania
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding	Seed, total disclosed ~$8,400,000 [AFR, October 2026]

How the Company Got Here

PUBLIC Skopos Bio enters the record as a newly formed Melbourne radiopharmaceutical company with a very specific scientific starting point: it is building around theranostic cancer targets that emerged from Peter MacCallum Cancer Centre research, rather than arriving with a broad platform story first [Skopos Bio, retrieved 2026]. The company website describes Skopos as developing "next generation radiopharmaceutical therapies," and public reporting places its headquarters in Melbourne, Australia [Skopos Bio, retrieved 2026].

The chronology is short but clear on the public evidence. Skopos Bio was founded in 2024, according to the structured company facts provided for this report, and its public-facing materials show a company focused on radiopharmaceutical therapies for oncology from the outset [Skopos Bio, retrieved 2026]. The named founding team, Michael Hofman, Mohammad Haskali, and Luc Furic, each hold senior research or clinical roles at Peter MacCallum Cancer Centre, which supports the characterization of the business as an academic spinout rather than a conventional de novo biotech formation [Skopos Bio, retrieved 2026].

Its first visible milestone appears to be public launch rather than clinical readout. The company website states that Skopos is building an oncology pipeline around a theranostic approach that pairs imaging with treatment for patients with limited options, but the site does not surface legal entity details or a longer operating history in the materials reviewed here [Skopos Bio, retrieved 2026]. On the available company-source evidence, the overview is best read as an early-stage spinout with a defined scientific origin, a Melbourne base, and a still-forming corporate profile [Skopos Bio, retrieved 2026].

Product and Technology

MIXED

What is public here is narrower than the financing coverage might suggest. Skopos Bio describes itself as developing "next generation radiopharmaceutical therapies," and public reporting is directionally consistent on the underlying modality: targeted radioactive molecules intended to find cancer cells and deliver radiation more selectively than conventional systemic approaches [Skopos Bio, retrieved 2026] [EM Advisory, October 2026] [LinkedIn, retrieved 2026]. Trade coverage and the company site also frame the work as a theranostic platform, meaning a pairing of imaging and treatment around shared biological targets, with the initial disease focus in prostate cancer [Skopos Bio, retrieved 2026] [SmartCompany, retrieved 2026] [EM Advisory, October 2026].

The technical edge, based on public evidence, appears to sit less in disclosed platform architecture and more in founder domain expertise around radiochemistry, nuclear medicine, and prostate cancer biology. Peter MacCallum Cancer Centre profiles confirm that Michael Hofman leads the Prostate Theranostics and Imaging Centre of Excellence, Mohammad Haskali is the centre's inaugural Chief Radiopharmaceutical Scientist, and Luc Furic's lab focuses in part on identifying and validating novel theranostic targets for prostate cancer [Peter MacCallum Cancer Centre, retrieved 2026] [The University of Melbourne, retrieved 2026]. That does not by itself validate clinical differentiation, but it does support the view that the company is being built from a research base closely aligned with the chosen modality and first indication [Peter MacCallum Cancer Centre, retrieved 2026].

What remains unproven is equally important. Public materials indicate Skopos is preclinical and raising capital to advance research and development toward human trials, but they do not disclose named assets, target classes, preclinical datasets, isotope choices, manufacturing strategy, or any verified demo of efficacy or safety [EM Advisory, October 2026] [SmartCompany, retrieved 2026]. For now, the product story is credible at the modality level and thin at the asset level, which is typical for a newly launched academic spinout but still leaves investors underwriting scientific translation more than product execution.

Lightly corroborated -- Based on company website and trade coverage, with partial corroboration from Peter MacCallum Cancer Centre profiles; key product specifics remain company-led or undisclosed.

Where the Demand Sits

PUBLIC

The market matters now because radiopharmaceutical oncology has moved from a niche research track to a funded development area, and Skopos Bio is entering at a point when capital, clinical attention, and strategic buyer interest are all increasingly aligned around targeted radiation approaches [AFR, October 2026] [Drug Discovery World, October 2026].

Public evidence on Skopos Bio's addressable market is narrow, which limits any clean TAM, SAM, and SOM build for this section. The only cited demand figure in the source set is for the company's initial indication: prostate cancer accounts for approximately 1.5 million diagnoses globally each year, according to Drug Discovery World's October 2026 coverage of the company [Drug Discovery World, October 2026]. That is best read as an incidence marker rather than a revenue market size, and it should not be stretched into a market estimate without pricing, line-of-therapy, or eligible-patient assumptions that are not in the public record.

Even with that constraint, the market logic is legible. Skopos says it is pursuing a theranostic model that pairs imaging with treatment in oncology, initially in prostate cancer and potentially across additional targets over time [Skopos Bio, retrieved 2026] [EM Advisory, October 2026]. That places the company at the intersection of several adjacent markets rather than one isolated product niche: prostate cancer therapeutics, nuclear medicine imaging, and radioligand or radiopharmaceutical treatment platforms. For investors, that usually means demand can be pulled by both clinical need and workflow familiarity if the underlying biology and manufacturing path hold up.

Segment	Public sizing claim	Relevance to Skopos
Initial target indication: prostate cancer	Approximately 1.5 million global diagnoses annually [Drug Discovery World, October 2026]	Establishes the incidence pool for the first stated disease focus

The available public number is small in scope, but it is directionally useful. It suggests Skopos has chosen a common cancer type for its opening program, which can matter more at seed stage than a broad but weakly specified platform narrative.

Demand drivers are clearer than formal market sizing. One driver is persistent clinical need in hard-to-treat cancers, which is the frame used in both company and transaction coverage of Skopos's program [Skopos Bio, retrieved 2026] [EM Advisory, October 2026]. A second is the theranostic approach itself, where imaging and treatment are linked around the same or related biological targets, an area that Peter Mac's own research programs publicly emphasize in prostate cancer through target identification and validation work [Peter MacCallum Cancer Centre, retrieved 2026]. A third is financing appetite: the company's AUD$12 million seed round, reported by AFR and others, indicates that specialist and adjacent-health investors are willing to back new radiopharma formation in Australia despite the long preclinical path [AFR, October 2026] [Angellinx, October 2026].

There are also practical market tailwinds in founder-market fit. Michael Hofman, Mohammad Haskali, and Luc Furic all hold senior roles connected to prostate theranostics, radiopharmaceutical science, or translational prostate cancer research at Peter MacCallum Cancer Centre, according to Peter Mac and University of Melbourne profiles [Peter MacCallum Cancer Centre, retrieved 2026] [The University of Melbourne, retrieved 2026]. That does not reduce development risk, but it does matter in a category where target selection, radiochemistry, translational science, and clinical workflow design tend to be tightly coupled.

Substitutes and adjacent markets deserve equal weight because they shape the ceiling as much as the opportunity. In prostate cancer, radioligand therapies compete indirectly with existing systemic oncology treatments and with diagnostic pathways that do not require paired radiopharmaceutical development. More broadly, radiopharma programs also sit beside platform oncology modalities that target tumors through different payloads or mechanisms. The public sources here do not quantify those adjacent categories, so the safer inference is qualitative: Skopos is not creating demand from scratch, but it does need to prove that its targets and molecules can earn a place within already crowded treatment sequences [Skopos Bio, retrieved 2026] [Seedtable].

Regulatory and macro forces cut both ways. On the positive side, the company is explicitly building toward human clinical trials, and that milestone orientation is often what allows radiopharmaceutical startups to move from academic credibility to pharma relevance [SmartCompany] [EM Advisory, October 2026]. On the constraining side, the public record still places Skopos in preclinical development, which means the timeline remains exposed to the usual biotech gating items: preclinical package quality, manufacturing readiness, regulator engagement, and the economics of scaling radioactive supply chains. None of those are unique to Skopos, but all of them are material to market capture in radiopharma, where a good target alone is rarely enough [SmartCompany] [Skopos Bio, retrieved 2026].

Lightly corroborated -- Market sizing evidence in this section rests mainly on one third-party trade source, with company and institutional sources supporting indication focus and theranostic context.

Competitive Landscape

Competitive Positioning

MIXED Skopos Bio is entering radiopharmaceutical oncology from a research-heavy starting point, with its clearest public distinction resting on founder expertise and Peter MacCallum Cancer Centre roots rather than on disclosed clinical data or commercial infrastructure [Drug Discovery World, October 2026] [Peter MacCallum Cancer Centre] [Skopos Bio, retrieved 2026].

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Skopos Bio	Developing targeted radioactive molecules for cancer, initially focused on prostate cancer and a broader theranostic pipeline	Seed, AUD$12 million reported in October 2026	Founding team comes from Peter MacCallum Cancer Centre, including leaders in prostate theranostics and radiopharmaceutical science	[AFR, October 2026] [Drug Discovery World, October 2026] [Peter MacCallum Cancer Centre]
Zinklar	Named competitor in the structured research	Not established in the supplied public sources	Not established in the supplied public sources	[Structured facts]

The competitive map is still thin in public view, and that matters. On the evidence available, Skopos sits in the challenger tier of radiopharmaceutical developers: preclinical, newly funded, and focused on a targeted oncology wedge rather than a broad commercial portfolio [EM Advisory, October 2026] [SmartCompany] [AFR, October 2026]. The incumbent reference set is not named in the supplied public record, but the adjacent substitute is clear enough: established cancer-treatment pathways that do not rely on radioligand or theranostic delivery. Skopos is therefore competing first for scientific validation and clinical progression, before it can compete for prescribing share.

Its edge today is human capital, and the sourcing is better here than in most other parts of the file. Michael Hofman is publicly identified as Director of the Prostate Theranostics and Imaging Centre of Excellence at Peter Mac, Mohammad Haskali as Peter Mac's inaugural Chief Radiopharmaceutical Scientist, and Luc Furic as Head of Translational Prostate Cancer Research at Peter Mac [Peter MacCallum Cancer Centre] [The University of Melbourne, retrieved 2026]. That combination suggests unusually tight alignment between target biology, radiochemistry, and clinical theranostics. It is a real advantage in company formation and early program selection, but it is perishable unless it converts into proprietary assets, clinical proof, or partner access. Academic prestige helps at seed, less so once manufacturing, trials, and regulatory execution become the binding constraints.

The exposure is straightforward. Even so, Skopos's own disclosed position creates a visible weakness: it has announced financing and scientific ambition, but not clinical results, product deployments, or partnerships that would widen the moat beyond the founding team [AFR, October 2026] [Skopos Bio, retrieved 2026]. In practical terms, a better-capitalized radiopharma peer, or any competitor that reaches the clinic sooner in prostate cancer, would hold the near-term advantage because time-to-human-data tends to shape partner attention and future fundraising.

The most plausible 18-month scenario is a sorting event around translational execution rather than branding. Winner if X: Skopos, if the company can move its lead program credibly toward human trials and show that its Peter Mac-origin science translates into a differentiated theranostic target set [SmartCompany] [Peter MacCallum Cancer Centre]. Loser if Y: Zinklar, if it remains less visible or less clinically advanced than Skopos in the same investor conversation. The reverse also holds. If a named rival reaches the clinic first while Skopos remains in preclinical development, the competitive narrative will likely shift away from founder pedigree and toward proof of execution.

Single unverified source -- The section is grounded in AFR, Drug Discovery World, Peter MacCallum Cancer Centre, The University of Melbourne, and the company website for Skopos-specific facts, but competitor-specific evidence is limited because the supplied public research names Zinklar without corroborating detail.

Opportunity

Upside case

Public sources If Skopos Bio executes, the prize is not a single prostate-cancer asset but a repeatable radiopharmaceutical discovery engine that can generate multiple theranostic programs for cancers where precision targeting materially changes outcomes [Skopos Bio, retrieved 2026] [Peter MacCallum Cancer Centre, retrieved 2026].

The headline opportunity rests on an unusual starting point for a seed-stage biotech: the company is coming to market with a founding group whose public records are anchored in prostate cancer theranostics and radiopharmaceutical science, rather than in a purely financial spinout story [Peter MacCallum Cancer Centre, retrieved 2026] [The University of Melbourne, retrieved 2026]. Skopos Bio says it is building a pipeline around theranostic targets in oncology, and outside coverage describes its program as targeted radioactive molecules intended to diagnose and treat cancer while limiting damage to healthy tissue [Skopos Bio, retrieved 2026] [EM Advisory, October 2026] [SmartCompany, retrieved 2026]. That does not make platform success likely, but it does make the upside legible: if the company can translate one target into human proof of concept, the same scientific and manufacturing playbook could support follow-on assets across adjacent solid-tumor settings.

The public evidence supports a few distinct scale paths rather than one monolithic outcome. The table below frames those paths conservatively, with catalysts tied to milestones that are standard for radiopharmaceutical companies rather than speculative category jumps.

Scenario	What happens	Catalyst	Why it's plausible
Prostate beachhead	Skopos advances its initial prostate cancer program into the clinic and becomes a credible specialist developer in prostate theranostics	Entry into human trials after preclinical work [SmartCompany, retrieved 2026]	The company is initially targeting prostate cancer, and the founders' public work is concentrated in prostate theranostics and translational prostate cancer research [EM Advisory, October 2026] [Peter MacCallum Cancer Centre, retrieved 2026]
Multi-asset radioligand platform	One successful lead program validates a broader discovery engine and lets Skopos expand into additional oncology targets	Preclinical validation of additional theranostic targets from the pipeline [Skopos Bio, retrieved 2026]	The company publicly describes a pipeline exploring oncology targets, not a single molecule, and Luc Furic's lab has a stated focus on identifying and validating novel theranostic targets for prostate cancer [Skopos Bio, retrieved 2026] [Peter MacCallum Cancer Centre, retrieved 2026]
Partnered radiopharma builder	Skopos becomes an attractive licensing or collaboration counterparty for larger oncology or radiopharma players once early human data de-risks the platform	Human proof-of-concept data in an initial indication [SmartCompany, retrieved 2026] [Drug Discovery World, October 2026]	The company launched with institutional backing from Tenmile, Tin Alley Ventures, and Yosemite, which suggests access to capital and networks needed to pursue a partnered path if the science clears early milestones [AFR, October 2026] [CB Insights, retrieved 2026]

What compounding looks like here is scientific, not social. In radiopharmaceuticals, one program can create use for the next through target-validation know-how, radiochemistry capability, translational biology, and clinical-development pattern recognition, especially when imaging and therapy are paired under a theranostic model [Skopos Bio, retrieved 2026] [Peter MacCallum Cancer Centre, retrieved 2026]. The early signs are still preclinical, but the ingredients of a flywheel are visible in public sources: Hofman leads ProsTIC, Haskali's role centers on radiopharmaceutical science, and Furic's research agenda includes identifying novel theranostic targets [Peter MacCallum Cancer Centre, retrieved 2026] [The University of Melbourne, retrieved 2026]. If that combination yields one asset with clinical signal, the next assets should be faster to prioritize and easier to finance, because investors and potential partners will be underwriting a demonstrated team and approach rather than a first experiment.

The size of the win is easiest to frame through indication value and platform optionality, even though hard market benchmarks are limited in the sourced material. One trade source puts global annual prostate-cancer diagnoses at about 1.5 million, which at minimum indicates that the initial wedge is clinically meaningful rather than niche [Drug Discovery World, October 2026]. A more concrete financial framing is this: if Skopos reaches the point where it is viewed as a differentiated radiopharma platform with clinical proof in prostate cancer and credible follow-on assets, the company could plausibly become a several-hundred-million-dollar enterprise or more in private or strategic value, because buyers would be paying for both the lead program and the repeatability of the discovery engine (scenario, not a forecast). That upside case remains conditional on human data, but the public record is sufficient to say the ambition is grounded in a real therapeutic modality, a real founding bench, and a real first indication.

Lightly corroborated -- Section relies on a mix of company statements, trade coverage, and institutional biographies, with limited independent operating data and no public clinical results yet.

Sources